Bavarian Nordic (OTCMKTS:BVNRY) Short Interest Up 50.0% in August

Bavarian Nordic (OTCMKTS:BVNRY) saw a significant increase in short interest in August. As of August 14th, there was short interest totaling 633 shares, an increase of 50.0% from the July 30th total of 422 shares. Currently, 0.0% of the company’s stock are short sold. Based on an average trading volume of 1,666 shares, the short-interest ratio is presently 0.4 days.

Bavarian Nordic Trading Up 2.6%

Shares of BVNRY stock opened at $11.21 on Tuesday. The business’s fifty day simple moving average is $9.53 and its 200-day simple moving average is $9.72. Bavarian Nordic has a 12-month low of $8.67 and a 12-month high of $13.00. The company has a market cap of $2.67 billion, a PE ratio of 11.33 and a beta of 1.20.

Bavarian Nordic (OTCMKTS:BVNRY) last issued its quarterly earnings results on Friday, August 21st. The company reported $0.46 earnings per share for the quarter. The business had revenue of $316.47 million during the quarter. Bavarian Nordic had a return on equity of 12.06% and a net margin of 24.36%.

About Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company specializing in the development, manufacture and commercialization of vaccines and immunotherapies. Founded in 1994 and headquartered in Martinsried, Germany, the company combines internal research capabilities with in-house manufacturing to address serious infectious diseases and cancer indications. Bavarian Nordic’s operations encompass preclinical research, clinical development and commercial supply, with a strategic focus on leveraging its proprietary viral vector platforms.

The company’s commercial portfolio includes approved prophylactic vaccines such as Jynneos™ (marketed as Imvamune®/Imvanex®) for the prevention of smallpox and monkeypox in the United States, European Union and Canada; Rabipur® for rabies prevention; and Encepur® against tick-borne encephalitis.